4.6 Article

Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells

Journal

ONCOIMMUNOLOGY
Volume 6, Issue 5, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1311433

Keywords

Antitumor immunity; calreticulin; cancer immunotherapy; dendritic cells; heat-shock treatment; hyperthermia; immunogenic cell death

Funding

  1. Sotio a.s.
  2. Ministry of Education, Youth and Sports of the Czech Republic [LQ1604]
  3. project BIOCEV [CZ.1.05/1.1.00/02.0109]
  4. Ministry of Health, Czech Republic-Conceptual Development of Research Organization (University Hospital Motol, Prague, Czech Republic) [00064203]
  5. [RVO 61388971]

Ask authors/readers for more resources

The mechanisms of immunogenicity underlying mild heat-shock (mHS) treatment < 42 degrees C of tumor cells are largely attributed to the action of heat-shock proteins; however, little is known about the immunogenicity of tumor cells undergoing severe cytotoxic heat-shock treatment (sHS > 43 degrees C). Here, we found that sHS, but not mHS (42 degrees C), induces immunogenic cell death in human cancer cell lines as defined by the induction of ER stress response and ROS generation, cell surface exposure of calreticulin, HSP70 and HSP90, decrease of cell surface CD47, release of ATP and HMGB1. Only sHS-treated tumor cells were efficiently killed and phagocytosed by dendritic cells (DCs), which was partially dependent on cell surface calreticulin. DCs loaded with mHS or sHS-treated tumor cells displayed similar level of maturation and stimulated IFNg-producing CD8(+)C T cells without any additional adjuvants in vitro. However, only DCs loaded with sHS-treated tumor cells stimulated antigen-specific CD4(+) T cells and induced higher CD8(+) T-cell activation and proliferation. sHS-treated murine cells also exposed calreticulin, HSP70 and HSP90 and activated higher DC maturation than mHS treated cells. Vaccination with sHS-treated tumor cells elicited protective immunity in mice. In this study, we defined specific conditions for the sHS treatment of human lung and ovarian tumor cells to arrive at optimal ratio between effective cell death, immunogenicity and content of tumor antigens for immunotherapeutic vaccine generation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Multidisciplinary

Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling

Ladislav Sivak, Vladimir Subr, Jirina Kovarova, Barbora Dvorakova, Milada Sirova, Blanka Sihova, Eva Randarova, Michal Kraus, Jakub Tomala, Martin Studenovsky, Michaela Vondrackova, Radislav Sedlacek, Petr Makovicky, Jitka Fucikova, Sarka Vosahlikova, Radek Spisek, Libor Kostka, Tomas Etrych, Marek Kovar

Summary: Repurposing drug strategy using P-RD nanomedicine has successfully identified the anticancer effects of RD on cancer cells, which has been validated in mice experiments and human cancer cell lines, making it a promising therapeutic candidate with great potential for deep preclinical investigation.

JOURNAL OF CONTROLLED RELEASE (2021)

Article Biology

Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist

Caleb R. Glassman, Leon Su, Sonia S. Majri-Morrison, Hauke Winkelmann, Fei Mo, Peng Li, Magdiel Perez-Cruz, Peggy P. Ho, Ievgen Koliesnik, Nadine Nagy, Tereza Hnizdilova, Lora K. Picton, Marek Kovar, Paul Bollyky, Lawrence Steinman, Everett Meyer, Jacob Piehler, Warren J. Leonard, K. Christopher Garcia

Summary: Interleukin-2 (IL-2) is a pleiotropic cytokine that mediates both pro- and anti-inflammatory functions, with different sensitivities in immune cells due to cell type and activation state-dependent expression of receptors and signaling pathway components. Using structure-based design, IL-2 variants were created to titrate maximum signal strength across cell types, leading to cell type-dependent differences in gene expression. IL-2 partial agonists can be used to calibrate intrinsic differences in response thresholds across responding cell types to narrow pleiotropic actions.

ELIFE (2021)

Article Biology

IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25+Foxp3- T cells

Jakub Tomala, Petra Weberova, Barbora Tomalova, Zuzana Jiraskova Zakostelska, Ladislav Sivak, Jirina Kovarova, Marek Kovar

Summary: The IL-2 and JES6-1 mAb complexes selectively expand CD25(+) cells and T-reg cells, but also increase sensitivity to LPS shock in mice, potentially raising safety concerns for their use in immunotherapy.

ELIFE (2021)

Article Biochemistry & Molecular Biology

Simultaneous Delivery of Doxorubicin and Protease Inhibitor Derivative to Solid Tumors via Star-Shaped Polymer Nanomedicines Overcomes P-gp- and STAT3-Mediated Chemoresistance

Libor Kostka, Ladislav Sivak, Vladimir Subr, Jirina Kovarova, Milada Sirova, Blanka Rihova, Radislav Sedlacek, Tomas Etrych, Marek Kovar

Summary: The derivative of protease inhibitor ritonavir (RD) was found to be a potent P-gp inhibitor and cancerostatic drug. In this study, high-molecular-weight HPMA copolymer conjugates with a PAMAM dendrimer core bearing both doxorubicin (Dox) and RD (Star-RD + Dox) were designed to increase the circulation half-life and maximize simultaneous delivery of Dox and RD into the tumor. It was found that Star-RD + Dox exhibited higher cytostatic and proapoptotic activities compared to other treatments in vitro, and also inhibited STAT3 signaling in vivo.

BIOMACROMOLECULES (2022)

Article Nanoscience & Nanotechnology

Metastatic spread inhibition of cancer cells through stimuli-sensitive HPMA copolymer-bound actinonin nanomedicines

Jana Kousalova, Milada Sirova, Libor Kostka, Vladimir Subr, Jirina Kovarova, Katerina Behalova, Martin Studenovsky, Marek Kovar, Tomas Etrych

Summary: This study describes the design, synthesis, physicochemical and biological characteristics of water-soluble copolymer conjugates bearing actinonin for advanced drug delivery and inhibition of metastatic spread. The developed nanosystems showed favorable drug release kinetics and effectively inhibited the metastatic spread of cancer cells, highlighting their potential clinical application.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2022)

Article Microbiology

Pertussis toxin suppresses dendritic cell-mediated delivery of B. pertussis into lung-draining lymph nodes

Nela Klimova, Jana Holubova, Gaia Streparola, Jakub Tomala, Ludmila Brazdilova, Ondrej Stanek, Ladislav Bumba, Peter Sebo

Summary: The pertussis toxin PT inhibits migration of infected dendritic cells from the lungs to the draining lymph nodes, delaying the induction of adaptive serum antibody responses to infection. This suggests that PT action allows time for B. pertussis proliferation on the airway mucosa to facilitate transmission among humans.

PLOS PATHOGENS (2022)

Article Pharmacology & Pharmacy

HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo

Martin Studenovsky, Anna Rumlerova, Jirina Kovarova, Barbora Dvorakova, Ladislav Sivak, Libor Kostka, Daniel Berdar, Tomas Etrych, Marek Kovar

Summary: Mebendazole and other benzimidazole antihelmintics possess antitumour activity, but their poor water-solubility limits their bioavailability. A HPMA copolymer-based conjugate with mebendazole was developed to improve solubility and tumor accumulation. In vitro and in vivo experiments showed significant antitumour activity, which was further improved when combined with IL-2 and anti-IL-2 mAb.

PHARMACEUTICS (2022)

Article Cell Biology

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

Derek VanDyke, Marcos Iglesias, Jakub Tomala, Arabella Young, Jennifer Smith, Joseph A. Perry, Edward Gebara, Amy R. Cross, Laurene S. Cheung, Arbor G. Dykema, Brian T. Orcutt-Jahns, Tereza Henclova, Jaroslav Golias, Jared Balolong, Luke M. Tomasovic, David Funda, Aaron S. Meyer, Drew M. Pardoll, Joanna Hester, Fadi Issa, Christopher A. Hunter, Mark S. Anderson, Jeffrey A. Bluestone, Giorgio Raimondi, Jamie B. Spangler

Summary: Researchers have developed a fusion protein called F5111 immunocytokine (IC) that selectively activates and expands Tregs, providing a potential treatment for autoimmune diseases. This approach overcomes the limitations of traditional IL-2 treatment by preferentially stimulating Tregs while limiting off-target immune cell activation.

CELL REPORTS (2022)

Article Immunology

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

Zuzana Antosova, Nada Podzimkova, Jakub Tomala, Katerina Augustynkova, Katerina Sajnerova, Eva Nedvedova, Milada Sirova, Guy de Martynoff, David Bechard, Ulrich Moebius, Marek Kovar, Radek Spisek, Irena Adkins

Summary: SOT101, a potential clinical candidate for cancer treatment, activates NK cells and CD8(+) T cells and enhances their cytotoxicity against tumor cells. When used in combination with approved monoclonal antibodies, it increases the killing of tumor cells. In an animal model, the combination of SOT101 and Daratumumab showed the strongest anti-tumor effect, supporting further investigation of this combination in clinical studies.

FRONTIERS IN IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

Combined in vitro and cell-based selection display method producing specific binders against IL-9 receptor in high yields

Maros Huliciak, Lada Biedermanova, Daniel Berdar, Stepan Herynek, Lucie Kolarova, Jakub Tomala, Pavel Mikulecky, Bohdan Schneider

Summary: We used cell-free ribosome display and cell-based yeast display selection to develop specific protein binders for the extracellular domain of the human interleukin 9 receptor alpha (IL-9R alpha). By combining the strengths of ribosome display and yeast display, we optimized the protocol to produce highly specific binders to the target, including selectivity for common proteins and potential competitors. The binders were trained from DNA libraries of two protein scaffolds and proved effective for the medically relevant molecular target.

FEBS JOURNAL (2023)

Article Chemistry, Multidisciplinary

Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models

Libor Kostka, Lenka Kotrchova, Eva Randarova, Carolina A. Ferreira, Iva Malatova, Hye Jin Lee, Aeli P. Olson, Jonathan W. Engle, Marek Kovar, Weibo Cai, Milada Sirova, Tomas Etrych

Summary: nanomedicines are being developed as an improved therapeutic option with reduced side effects, and this study introduces tailored nanosystems for the treatment of solid tumors or hematological malignancies. The relationship between the structure of the nanosystem and its distribution in the body was evaluated through independent assessments of the polymer carrier and drug pharmacokinetics. The results showed enhanced tumor accumulation of the polymer carriers in mice with solid tumors, as well as significant accumulation of doxorubicin bound to the polymer carriers in specific tumor types.

JOURNAL OF CONTROLLED RELEASE (2023)

Article Biology

Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2

Oksana Tsyklauri, Tereza Chadimova, Veronika Niederlova, Jirina Kovarova, Juraj Michalik, Iva Malatova, Sarka Janusova, Olha Ivashchenko, Helene Rossez, Ales Drobek, Hana Vecerova, Virginie Galati, Marek Kovar, Ondrej Stepanek

Summary: In this study, it was identified that Tregs limit the availability of IL-2, thereby suppressing the formation of a previously uncharacterized subset of antigen-stimulated KILR CD8(+) effector T cells. These KILR CD8(+) T cells exhibit superior cell-killing abilities and can be induced by the administration of agonistic IL-2 immunocomplexes. This research has potential implications for immunotherapy targeting these cells in humans.

ELIFE (2023)

Article Cell Biology

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients

Peter Holicek, Iva Truxova, Jana Rakova, Cyril Salek, Michal Hensler, Marek Kovar, Milan Reinis, Romana Mikyskova, Josef Pasulka, Sarka Vosahlikova, Hana Remesova, Iva Valentova, Daniel Lysak, Monika Holubova, Petr Kaspar, Jan Prochazka, Lenka Kasikova, Radek Spisek, Lorenzo Galluzzi, Jitka Fucikova

Summary: While type I interferon (IFN) plays a key role in fighting viral infections, recent data indicates that it also promotes cancer immunosurveillance and enhances the effectiveness of antineoplastic agents. Researchers have discovered that malignant blasts in patients with acute myeloid leukemia (AML) release type I IFN through a Toll-like receptor 3 (TLR3)-dependent mechanism. Although immunosuppressive mechanisms hinder the anticancer immune response stimulated by type I IFN in these patients, it has been found to have direct cytostatic, cytotoxic, and chemosensitizing effects on AML cells and stem cells, as well as prognostic value in AML patients.

CELL DEATH & DISEASE (2023)

No Data Available